title: Lamivudine therapy of chronic hepatitis B in three groups of patients: non transplanted patients, liver recipients, and kidney recipients.
abstract: OBJECTIVE
  As conflicting results have been observed by some authors in liver recipients, the aim of the study was to evaluate lamivudine therapy in 3 groups of patients with chronic hepatitis B: non-transplanted patients, liver and kidney recipients.
  
  
  METHODS
  All patients were studied for clinical symptoms, hepatic enzymes, hepatitis B virus (HBV) serology, serum HBV DNA load, and HBV polymerase genotype (mutations associated with lamivudine resistance).
  
  
  RESULTS
  During the 48-144 week-long follow-up (mean: 75 weeks), 23 non-transplanted patients, 5 liver and 6 kidney recipients were studied. A sustained biochemical and virological response was obtained in 19 out of the 23 non-transplanted patients and in 4 of 6 kidney recipients, while the 5 liver recipients did not respond. After the development of lamivudine resistance, mutations rtM204V and rtL180M were detected in all studied patients, mutation rtM207I in one, with similar results from traditional nucleotide sequencing and a commercial line probe assay.
  
  
  CONCLUSIONS
  The poor response to lamivudine in liver recipients requires further studies.
authors.affiliation: Laboratoire de Virologie, Université Victor-Ségalen, Bordeaux, France.
authors.forename: Evelyne
authors.initials: E
authors.lastname: Schvoerer
authors.forename: Imed
authors.initials: I
authors.lastname: Kabissa
authors.forename: Emmanuelle
authors.initials: E
authors.lastname: Cotto
authors.forename: Anne-Christine
authors.initials: AC
authors.lastname: Jouvencel
authors.forename: Charles
authors.initials: C
authors.lastname: Balabaud
authors.forename: Victor
authors.initials: V
authors.lastname: De Ledinghen
authors.forename: Patrice
authors.initials: P
authors.lastname: Couzigou
authors.forename: André
authors.initials: A
authors.lastname: Quinton
authors.forename: Claire
authors.initials: C
authors.lastname: Schvoerer
authors.forename: Marie-Edith
authors.initials: ME
authors.lastname: Lafon
authors.forename: Hervé
authors.initials: H
authors.lastname: Fleury
authors.forename: Pierre-Henri
authors.initials: PH
authors.lastname: Bernard
mesh_terms: D000410:Alanine Transaminase / Q000097:blood; D004279:DNA, Viral / Q000097:blood; D004352:Drug Resistance, Microbial / Q000235:genetics; D005260:Female; D015684:Gene Products, pol / Q000235:genetics; D006515:Hepatitis B virus / Q000201:enzymology / Q000235:genetics; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D016030:Kidney Transplantation; D019259:Lamivudine / Q000627:therapeutic use*; D016031:Liver Transplantation; D008297:Male; D009154:Mutation; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D004279:DNA, Viral; D015684:Gene Products, pol; C066027:P protein, Hepatitis B virus; D019259:Lamivudine; D000410:Alanine Transaminase